In July 2012, David joined Index Ventures as a Venture Partner, where he was responsible for the creation, development and sale of XO1 and the creation of E3Bio.
James moved from UCL to the MRC London Institute of Medical Sciences in 2009 before taking up the position of Professor of Molecular Medicine in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow in 2017.
Simon joined the University of Cambridge in 2016 to undertake an NIHR Academic Clinical Lecturer post combining clinical practice in anaesthesia and intensive care with the development of his research programme investigating the mechanisms of vascular dysfunction in sepsis.
Francesco De Rubertis is a Partner and co-founder of medicxi. He joined Index Ventures in 1997 to launch the Life Sciences practice, where he spearheaded the creation and adoption of the asset-centric investment strategy - now one of the industry standards.